WEKO3
アイテム
?Comparative evaluation of radionuclide therapy using 90Y and 177Lu
https://repo.qst.go.jp/records/2000284
https://repo.qst.go.jp/records/2000284a5d7c8cb-bb06-4322-b9c8-7d861d5f5585
| アイテムタイプ | 学術雑誌論文 / Journal Article(1) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2023-08-07 | |||||||||||||||||||||
| タイトル | ||||||||||||||||||||||
| タイトル | ?Comparative evaluation of radionuclide therapy using 90Y and 177Lu | |||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 言語 | ||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||
| 著者 |
Hirofumi Hanaoka (Gunma Univ)
× Hirofumi Hanaoka (Gunma Univ)
× Kazuyuki Hashimoto (JAEA)
× Watanabe Satoshi
× Matsumoto Shojiro
× Sakashita Tetsuya
× Watanabe Shigeki
× Ishioka Noriko
× Keigo Endo (Gunma Univ)
|
|||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||
| 内容記述 | Objective Both 90Y and 177Lu are attractive β-emitters for radionuclide therapy and have been used in clinical practice. Nevertheless, comparative evaluation between 90Y- and 177Lu-labeled molecules has not been fully conducted. Thus, in this study, the features of 90Y and 177Lu for radionuclide therapy were assessed in tumor-bearing mice. Methods Two tumor cell lines with different growth rates were used. Biodistribution studies of 177Lu-labeled antibodies (177Lu-Abs) were conducted in each tumor-bearing mouse model. Subsequently, the therapeutic effect of 90Y- and 177Lu- Ab were assessed in tumor-bearing mice. The absorbed radiation dose for the tumor was estimated using the Monte Carlo simulation. Results 177Lu-Abs demonstrated high tumor accumulation in both tumor-xerograph. In the fast-growing tumor model, 90Y-Ab showed a better therapeutic effect than 177Lu-Ab, reflecting a higher absorbed radiation dose of 90Y-Ab than that of 177Lu-Ab. In the slow-growing tumor model, both 90Y- and 177Lu-Ab showed an excellent therapeutic effect; however, 177Lu-Ab had a longer efficacy period than 90Y-Ab, which could be attributed to the longer half-life and better dose uniformity of 177Lu than those of 90Y. Conclusions To accomplish a maximum therapeutic effect, selecting 90Y or 177Lu, to depend on the growth rate of individual cancer, would be helpful. |
|||||||||||||||||||||
| 書誌情報 |
Annals of Nuclear Medicine 巻 37, p. 52-59, 発行日 2022-11 |
|||||||||||||||||||||
| ISSN | ||||||||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||||||||
| 収録物識別子 | 0914-7187 | |||||||||||||||||||||
| DOI | ||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||
| 関連識別子 | 10.1007/s12149-022-01803-y | |||||||||||||||||||||
